Status:
COMPLETED
Composition for Treating Spermatogenesis and Semen Disorders / FPT-20
Lead Sponsor:
Trieu, Nguyen Thi, M.D.
Collaborating Sponsors:
TRAN MINH DUC, MD
Conditions:
Spermatogenesis and Semen Disorders
Eligibility:
MALE
25-40 years
Phase:
PHASE4
Brief Summary
Research to develop a new, natural-derived formulation that eliminates inflammatory tissue and regenerates new tissue of the lobules, epithelium of the tubules, and connective tissue surrounding the s...
Detailed Description
FPT-20 has stabilized cortisol levels, maintained stable B-lymphocytes in the body, verified by quantitative tests of blood B-lymphocytes and blood cortisol, cut off the chronic inflammation chain, pr...
Eligibility Criteria
Inclusion
- The selected person has evidence of spermatogenesis disorder, no sperm, and weak sperm that do not meet the standards in terms of quantity and quality.
- There are signs of orchitis.
- Accepting patients with other comorbidities such as metabolic diseases, congenital or acquired immunodeficiency, HIV/AIDS, HBV, HCV, and Tuberculosis.
Exclusion
- Do not select patients with advanced cancer.
Key Trial Info
Start Date :
October 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 20 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05399212
Start Date
October 29 2020
End Date
May 20 2022
Last Update
May 16 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Saigon Biopharma LLC
Wilmington, Delaware, United States, 19801-6601
2
Saigon Biopharma Company Limited
Hồ Chí Minh, Ho Chi Minh City, Vietnam, 700000